Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA decision on BPA due by Nov. 30

This article was originally published in The Tan Sheet

Executive Summary

Following internal and external scientific reviews of the potential risks of low-dose exposure to bisphenol A, the agency will decide how to proceed by Nov. 30, according to acting Chief Scientist Jesse Goodman. Should FDA determine the chemical does not meet the standard of reasonable certainty of no harm, it "would announce its intent to initiate formal rulemaking to repeal or restrict some or all uses of BPA in food contact substances," Goodman said at the FDA Science Board meeting Aug. 17. Likewise, if BPA is found to meet the standard, FDA would release the review assessment, explain the results and provide advice for consumers, he added. Commissioner Margaret Hamburg told lawmakers in June of FDA's intent to reassess whether BPA is safe in food and beverage containers; the food safety bill passed by the House, H.R. 2749, would require FDA to advise Congress of its conclusion on BPA by the end of 2009 (1"The Tan Sheet" June 22, 2009)

You may also be interested in...



BPA Study Added To Food Safety Bill, But Supplements Remain “Gray Area”

The House Energy and Commerce Committee added a requirement that FDA reassess bisphenol A risks before approving a food safety reform bill

Legal Notebook: Catalyst’s Suit vs. FDA Is Tossed, Avonex Patent Invalidity Verdict Is Reinstated

Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.

Naturopath Marketing Brain Defense Supplement Anticipates Support For Making TBI Claims

Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel